Exact Sciences Corporation (FRA:EXK)

Market Cap	16.66B
Revenue (ttm)	2.63B
Net Income (ttm)	-840.86M
Shares Out	n/a
EPS (ttm)	-4.49
PE Ratio	n/a
Forward PE	120.84
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	46
Open	86.94
Previous Close	86.52
Day's Range	86.94 - 86.94
52-Week Range	33.80 - 88.16
Beta	n/a
RSI	67.63
Earnings Date	Feb 17, 2026

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Ri...

• Industry: Commercial Physical and Biological Research
• Founded: 1995
• Employees: 7,000
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: EXK

Financial Performance

In 2024, Exact Sciences's revenue was $2.76 billion, an increase of 10.37% compared to the previous year's $2.50 billion. Losses were -$1.03 billion, 404.0% more than in 2023.

Financial numbers in USD